Clinical Trial Update: Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents [Phase 4]

View source ↗

Summary

Phase 4 trial assessing effectiveness, safety, and immunogenicity of GSK Cervarix in healthy adolescents has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections
• Papillomavirus

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 4 | Status: COMPLETED | Results posted: 2016-01-26